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Background: In term newborns meconium ileus is frequently associated with cystic fibrosis. Reports on meconium
ileus in preterm infants being diagnosed with cystic fibrosis early after birth are very scarce. Associations between
genotype and phenotype in cystic fibrosis and its particular comorbidities have been reported.
Case presentation: Two extremely preterm twin infants (26 weeks of gestation) born from a Malaysian mother and
a Caucasian father were presented with typical signs of meconium ileus. Despite immediate surgery both displayed
a unique and finally lethal course. Mutation analysis revealed a novel, probably pathogenic cystic fibrosis mutation,
p.Cys524Tyr. The novel mutation might explain the severity of disease next to typical sequelae of prematurity.
Conclusion: Preterm neonates with meconium ileus have to be evaluated for cystic fibrosis beyond ethnical
boundaries, but may take devastating clinical courses despite early treatment. The novel, potentially pathogenic
CF mutation p.Cys524Tyr might be associated with severe meconium ileus in neonates. Disease-modifying loci are
important targets for intestinal comorbidity of cystic fibrosis.
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Reports on patients with significant prematurity, meconium
ileus (MI) and cystic fibrosis (CF) are scarce to the best
of our knowledge. Given the fact that ethnicity plays an
important role in the occurrence of CF it is of interest
to note that MI is generally rare in Malaysia, as is CF
in Asia [1]. In general, MI in neonates is thought to
account for more than 80% of diagnoses of CF, although
only 10-20% of CF patients develop MI [2,3].
Gorter et al. (2010) reported that preterm infants more
likely experienced MI without CF and had more complex
MI (perforation, atresia, necrosis, volvulus) [2]. The out-
come after surgery was favourable, whereas outcome after
intestinal perforation was associated with poor survival
[4]. Interestingly, survival does not differ between CF
patients with and without MI, although MI seems to
define more severe disease courses [3].* Correspondence: alexander.puzik@uniklinik-freiburg.de
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reproduction in any medium, provided the orThe role of genetic factors influencing severity and outcome
of CF is less well defined. Compound heterozygosity and dif-
ferent modifier loci seem to have a similar impact on disease
penetrance and comorbidities as the genotype itself [5-7].
We report on the unique and finally lethal course and
complications of extremely preterm twins being diagnosed
with a new CF mutation and review and discuss the
genetic impact on CF.Case presentation
Extremely preterm male twins (26 + 6/7 weeks of gestation,
birth weight 980 g and 920 g, monochorionic-diamniotic,
Malaysian mother, Caucasian father) were referred to us
from an affiliated hospital on day 9 of life for persistent
MI despite repetitive rectal irrigations.
Twin I displayed good cardiopulmonary adaptation
(Apgar score 7/9/9). Upon signs of ileus contrast X-ray of
the abdomen (administration per gastric tube) showed
immotility of the gut with contrast agent stopping at the
inflated, distended small intestine on day 5 (see Figure 1a).td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Initial X-rays of both twins. Chest and abdominal X-ray with contrast agent upon initial presentation of twin I (a) and II (b) showing
contrast agent stopping at the inflated, distended small intestine next to signs of neonatal respiratory distress syndrome.
Figure 2 Autopsy findings of twin I (histology). Pancreatic tissue shows distinctive PAS-positive intraductal mucous masses (♦) and dilatation
of the pancreatic ducts (rectangles). PAS staining, A 10×, B 20×. Consistent with meconium ileus the large intestine is filled with densely packed
stratified mucus (●) while the mucosa is flattened (▲). PAS staining, C 4×, D 10×.
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Figure 3 Abdomen of twin II after repeated unsuccessful surgery.
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tension of the distal small intestine, microcolon and
bowel adhesions. It was essential to form a Bishop-Koop
stoma. After starting to pass meconium and tolerating
oral feeding initially his haemoglobin level suddenly
dropped on day 28 and ultrasound showed intra-abdom-
inal effusion.
During re-laparotomy multiple hepatic haematoma and
bloody ascites were apparent, besides adhesions, multiple
coproliths and infarcted and perforated parts of the small
intestine. Necrotic parts of the intestine were resected and
the Bishop-Koop stoma was converted into two terminal
enterostomies. Abdominal wall closure was achieved with
a Goretex patch.
In addition, the patient developed respiratory and
circulatory failure and consumption coagulopathy. Due to
abdominal compartment syndrome the Goretex patch had
to be removed forming a laparostoma. He finally displayed
refractory metabolic acidosis leading to sudden bradycar-
dia with cardiac arrest.
Autopsy findings of twin I revealed heavily impacted
mucus in the small intestine and in crypts of the whole
colon. Pancreas histology showed dilated acini and ducts
filled up with mucus (see Figure 2a-d).
Twin II developed respiratory failure after birth necessi-
tating mechanical ventilation and surfactant administration
(Apgar score 3/7/7). Diagnostics on admission to our unit
were similar compared to twin I (see Figure 1b).
Explorative laparotomy on day 11 revealed complete
volvulus with partial gangrene of the ileum. There-
fore, 6 cm of ileum were resected and a T drainage was
placed in order to decompress the small intestine. During
all of the surgical procedures he exhibited circulatory
and renal failure requiring high dose vasopressors and
diuretics.
After failing to pass any meconium further surgery
with adhesiolysis and transformation of T drainage to
ileostoma was performed on day 25, which showed
stenosis of colon ascendens and partial infarction of
the small intestine. Due to distension the abdomen
had to be left open (see Figure 3). Using prokinetic drugs
(erythromycine, neostigmine) and enemas with N-acetyl-
cysteine some passing of stool could be achieved.
When finally off the ventilator on day 37, twin II
developed two spontaneous perforations next to the
duodenum, which led to fistulas in the surface of
the laparostoma. Without further surgical options at
this time he received permanent parenteral nutrition
via central venous lines, which led to three septic
episodes.
Moreover, after just 6 weeks of treatment a severe
hepatopathy with massive elevation of liver enzymes
and bilirubin (max. 30 mg/dl, direct 19 mg/dl) became
evident. At an age of 4 months liver synthesis functionsignificantly declined necessitating daily substitution of
plasma and albumin. A liver biopsy during next surgery
proved 50% fibrosis.
Finally, the last option was the reconstruction of
the continuity of the intestine. Unfortunately, soon
after successful adhesiolysis and anastomosis of the
remaining bowel 4 months after birth further spontan-
eous per-forations occurred and we decided to stop
therapy in compliance with the parents and after eth-
ical review.
Cystic Fibrosis Transmembrane Conductance Regula-
tor (CFTR) mutation analysis in both twins had been
performed after the first surgery, initially using the Cys-
tic Fibrosis v3Genotyping Assay (Abbott Laboratories,
Wiesbaden, Germany) and subsequently by Sanger sequen-
cing of the entire coding region (27 exons) and 50 bp of
flanking intronic sequences of the gene. Mutation analysis
showed compound heterozygosity for the common CFTR
mutation p.Phe508del (F508del or ΔF508, c.1521_1523
delCTT at the DNA level) and another, as yet unknown
mutation, p.Cys524Tyr (C524Y, c.1571G > A at the DNA
level), both in exon 11. Mutation analysis in the parents
revealed that the father was heterozygous p.Phe508del
mutation, and the mother was a heterozygous carrier
of the c.1571G > A mutation, thus confirming that
the mutations occurred on different alleles (in trans)
in the patients. Both the PolyPhen2 (http://genetics.
bwh.harvard.edu/pph2/) and Mutation Taster software
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c.1571G >A mutation as protein damaging.Discussion
The impact of compound heterozygosity on disease
course seems to depend on exact genotypes, as the
milder mutation seems to be dominant and lead to
milder courses [5]. Compound heterozygote ΔF508
patients differ from homozygote patients in degrees
of pancreas insufficiency and sweat chloride levels,
but not in the incidence of MI or lung function [6,7].
Especially the pancreas status of CF patients has been
related to certain genotypes [7].
Nevertheless, there have been described associations of
mutations like 621 + 1G- > T or G551D with the incidence
of MI [6,7]. In contrast, Zielinski et al. excluded specific
MI related CF mutations, but reported a higher incidence
of MI in patients with a CF modifier locus on chromosome
19q13 (CFM1 gene, encoding for a calcium-dependant
chloride channel) [5,8]. Further modifier loci (e.g. beta-
defensins) have been reported and seem to be equally
important in penetrance of MI and in lung function as
disease defining gene mutations [5,9].
We have found a novel CFTR mutation which has not
been previously described (http://www.genet.sickkids.on.
ca/cftr/) and also not been reported as a variant in the
1000 Genomes Database (http://browser.1000genomes.org/
index.html). A different, nonsense, mutation affecting the
same codon, c.1572C >A (p.Cys524*), has previously been
described in a CF patient [10]. Considering the position of
the mutation in the region encoding the first nucleotide
binding domain of the protein, it is highly likely that this
mutation, together with F508del, is responsible for the
CF in our patients.Conclusions
In conclusion we report on two extremely preterm male
twins who were compound heterozygous for a potentially
pathogenic, novel CF mutation, which might explain
the severity of their disease despite early treatment. Both
suffered from sequelae of prematurity and early onset CF,
which led to multi organ dysfunction. Preterm infants with
MI have to be evaluated for CF. Neonatal screening for CF
might contribute to early diagnosis and treatment. Disease
modifying loci have to be considered next to genotypes
when defining severity and comorbidities of CF.Consent
Written informed consent was obtained from the parents
for publication of this Case report and any accompanying
images. A copy of the written consent is available for
review by the Editor of this journal.Abbreviations
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